45
https://pubmed.ncbi.nlm.nih.gov/38093415
This study suggests that using cell-based quadrivalent influenza vaccine (QIVc) instead of egg-based vaccine (QIVe) for children and adolescents aged 6 months to 17 years in the US would reduce disease burden and be cost-saving from both payer and societal perspectives.
